more

IntraCellular Therapies (ITCI)

(Delayed Data from NSDQ)

$76.48 USD

+1.62 (2.16%)

Updated Jul 22, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News For Dec 24, 2019

by Zacks Equity Research Published on December 24,2019

Companies in the news are: ACB, APA, ITCI, SRPT

Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?

by Zacks Equity Research Published on December 20,2019

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% Higher

by Zacks Equity Research Published on December 11,2019

Intra-Cellular Therapies (ITCI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

medical

Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) Stock

by Zacks Equity Research Published on November 19,2019

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

Top Ranked Momentum Stocks to Buy for November 11th

by Zacks Equity Research Published on November 11,2019

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 11th

Intra-Cellular Therapies Shares March Higher, Can It Continue?

by Zacks Equity Research Published on October 30,2019

As of late, it has definitely been a great time to be an investor Intra-Cellular Therapies.

ITCIPositive Net Change

medical

Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

by Zacks Equity Research Published on September 27,2019

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

by Kinjel Shah Published on September 20,2019

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

by Zacks Equity Research Published on July 24,2019

Key highlights of the past week include earnings update, collaborations and other pipeline news.

Company News For Jul 9, 2019

by Zacks Equity Research Published on July 09,2019

Companies in the news are: AZZ, ITCI, DB and CTST

Intra-Cellular Therapies' Candidate Fails in Phase III Study

by Zacks Equity Research Published on July 09,2019

Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

biotechs

Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

by Zacks Equity Research Published on July 05,2019

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options

by Zacks Equity Research Published on June 17,2019

Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

by Zacks Equity Research Published on April 29,2019

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCIPositive Net Change

medical

Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on October 15,2018

Intra-Cellular Therapies has been struggling lately, but the selling pressure may be coming to an end soon.

ITCIPositive Net Change

Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock

by Zacks Equity Research Published on October 08,2018

Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.

ITCIPositive Net Change

medical

Company News For Nov 21, 2017

by Zacks Equity Research Published on November 21,2017

Companies In The News are: DY,TWX,RHHBY,ITCI

3 Reasons Why Intra-Cellular Therapies (ITCI) is a Great Momentum Stock

by Zacks Equity Research Published on September 11,2017

Intra-Cellular Therapies (ITCI) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.